(Australia-NewsWire.Com, February 07, 2018 ) Latin America Ovarian Cancer Therapeutics Market was worth $XX billion in 2016 and estimated to reach $XX billion by the end of 2021 with a CAGR of XX%. Ovarian cancer occurs when cell growth in the ovarian tissue becomes uncontrollable. Ovarian cancer is one of the most common causes of death in women across the world. The most common type of cancer among women is ovarian cancer. The treatment of ovarian cancer is done depending on the stage the disease is in. The treatment includes surgery, radiation, chemotherapy, and biological therapy. It is also known that ovarian cancer is the most chemo-sensitive cancer.
One of the factors is increase in aging of the women population. Introduction of new drugs and effective therapies, increase in people’s disposable income, and better government funding and support are some of the key factors behind the growth of global ovarian cancer market. Cases of ovarian cancer have grown rapidly, as a result, so has its therapeutics market. Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of the key factors restraining the growth for ovarian cancer market.
The Latin America ovarian cancer market is segmented based on the stage of cancer as Stage I, Stage II, Stage III and Stage IV. Stages of cancer are further sub-segmented into Stage IA, Stage IB, Stage IC, Stage IIA, Stage IIB, Stage IIC, Stage IIIA, Stage IIIB and Stage IIIC. By cancer type, it is segmented into Primary Peritoneal Carcinoma, Ovarian Stromal Tumors, Ovarian Germ Cell Tumors and Epithelial Ovarian Tumors. By Diagnosis, it is further segmented into Physical Examination, Blood Tests, Ultrasound, PET, CT Scan, MRI, Human Chorionic Gonadotropin Test and Biopsy, By type of treatment, it is segmented into Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery, Immunotherapy and Targeted Therapy. On the basis of geography, the Latin America market is analysed under various regions namely Argentina, Brazil, and Mexico.
Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc.
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.